MAPT and early-onset autosomal dominant Alzheimer disease: As is evident from Table 5, there is a large amount of data over the past decade showing that rapamycin prevents loss of cognition as well as Aβ and tau pathology seen in mouse models of Alzheimer’s disease, e.g., 10 studies using 7 different mouse models.